INTRODUCTION
The number of adolescents and young adults living with HIV (AYALHIV) continue to rise due to high rates of new infections and increasing life expectancy on antiretroviral therapy (ART). AYALHIV (between the ages of 10 to <25 years) account for 13% of those living with HIV; the majority of them are from sub-Saharan Africa (SSA). Adolescence is the only age group with a rising AIDS-related mortality [1] (Fig. 1) .
Adolescence, transition, and cancer risk
Historically, malignancies in people living with HIV are categorized as AIDS-defining and non-AIDSdefining (Table 1) [2, 3] . AYALHIV are at increased risk of developing both AIDS and non-AIDS-defining cancers compared to HIV-negative individuals [4] . The increased cancer risk for those living with HIV is driven by interlinked immunosuppression, decreased cancer surveillance, persistent coinfection with oncogenic viruses, and HIV viremia. Immediate ART initiation, before immunosuppression occurs, significantly reduces risk of cancer [5, 6 & ]. However, AYALHIV have lower rates of ART uptake, increased nonadherence to ART, and higher rates of loss to follow-up compared to younger children and older adults resulting in poorly controlled HIV [4, 7 Reducing the risk of cancer in AYALHIV requires increased access to suppressive antiretroviral therapy, HPV and HBV vaccination, screening and treatment for HBV/hepatitis C virus coinfection, and programmatic screening for cervical and anogenital cancers. Improvement in cancer estimates for AYALHIV requires data disaggregated by age and route of HIV transmission, which is currently lacking.
Enabling long-term follow-up of children and adolescents living with HIV, including survivors of a dual diagnosis of HIV and malignancy as they undergo transition into adult services, requires effective linkage of pediatric and adult cohorts. 
METHODS
We searched PubMed on November 2nd 2017 (search terms are shown in Table 2 ). We restricted the search to January 1st 2016 to November 1st 2017. We identified 289 references, which were reviewed by the authors. We included papers that reported cancer incidence rates, risk factors, survival, or prevention interventions in AYALHIV aged 10 to less than 25 years. Papers reporting incidence rate in adults without further age disaggregation for less than 25 year olds were not considered. We included original articles, systematic reviews, and case reports. Expert reviews were excluded. A few older important studies were used to support key statements.
CANCER EPIDEMIOLOGY IN ADOLESCENTS AND YOUNG ADULTS LIVING WITH HIV
In the recent literature, there were limited data on cancers disaggregated by age and virtually no data disaggregated by mode of HIV transmission. It was, therefore, not possible to describe differences in perinatally and horizontally infected AYALHIV. Although pediatric and adult cohorts linking is being developed [19 
Non-Hodgkin lymphoma
A single-center cohort study from the United Kingdom reported on the increased risk of a new lymphoma diagnoses in young adults living with perinatally acquired HIV (PaHIV) following transition to adult care [22] . A total of 5 out of 147 (3.4%) developed lymphoma at a median (range) age of 19 (18) (19) (20) (21) (22) (23) years. Patients presented with advanced disease (Ann Arbor stage III/IV) mainly diffuse large B-cell lymphomas, a prolonged history of nonadherence, with a life time average of 14 years with detectable viraemia and a low nadir CD4 cell count [157 (90-220) cells/ml]. Small numbers precluded formal risk factor analysis; however, the NHL incidence rate significantly exceeded that of the age matched general UK population; incidence rate ratio 25.9 (95% CI 8.31-61.7), P < 0.0001. Treatment outcomes were not reported. This study echoes a previous report from Italy, describing two cases of Burkitt lymphoma in AYALHIV who were chronically exposed to high-level HIV viremia [23] . These two case series support the concerns of longer term oncogenic risk for the current generation of perinatally infected AYALHIV who experienced prolonged viremia due to late diagnosis and have low rates of . A cohort study conducted in Uganda and Kenya reported crude Kaposi sarcoma incidence rates for AYALHIV (18-24 years) higher in ART nonusers than in ART users [13] . Incidence rates tended to be higher in young men than in women; [25] . A third study reported Kaposi sarcoma incidence rates for AYALHIV (aged 16-24 years) from Europe, South Africa, North America, and Asia. In this multiregional cohort analysis adolescents in South Africa had very high Kaposi sarcoma incidence rates (303, 95% CI 176-523) per 100 000 person years, followed by adolescents in Latin America, North America, and Europe (Table 3) .
Invasive cervical cancer
Cervical cancer is the fourth leading cause of cancer incidence and mortality for women globally [28, 29] . In AYALHIV, one cohort study reported an incidence rate for invasive cervical cancer (ICC) in young women (18-25 years) of 223 (100-496) per 100 000 person years [30 && ]. Women living with HIV have higher hrHPV prevalence [31, 32] and more diverse HPV subtypes than their HIV negative counterparts [33,34 & ,32]. HIV-infected young women have high incidence of cervical dysplasia [35] ; compared to HIVuninfected peers, the rate has been with reported incidence to be three times higher [36] .
Hepatocellular carcinoma
HIV/HBV and HIV/HCV coinfections are associated with an increased risk of liver disease including HCC in adults; however, there are minimal data in those coinfected either perinatally or in childhood [37 & ]. Two cases of HCC in adolescents are described in the literature. One male, of black African origin, with PaHIV/HBV developed a rapidly progressive HCC aged 19 despite more than a decade of suppressive ART for both HBV and HIV and regular HCC screening. Despite timely surgery, he died of recurrent metastatic HCC within a year of diagnosis [37 & ]. A second adolescent with PaHIV developed an HCC but with no evidence of hepatitis coinfection. He had slow disease progression despite being severely immunocompromised, with no evidence of recurrence more than a year from surgical resection [38] .
Smooth muscle tumours
A recent study from South Africa reported a case series of EBV-associated smooth muscle tumors in AYALHIV and adults [39] . Five cases occurred in adolescents (10-15 years) with median CD4 cell count 616 (range 1-1331) cells/ml; all were female, and all but one survived [39] .
TREATMENT, PROGNOSIS, AND SURVIVORSHIP
There were limited published data for cancer outcomes in AYALHIV; however, adult studies suggest [41] . Local first-line chemotherapy included bleomycin and vincristine (BV). In 2012, doxorubicin became available in Malawi, which was added for second-line therapy. Paclitaxel was used for the third line. ART-naïve individuals started nevirapine-based ART within 2 weeks of chemotherapy. Of all patients, 28% had severe immunosuppression and nearly half were on ART at time of Kaposi sarcoma diagnosis. The combination of BV was well tolerated with ART, with minimal severe adverse events. Over half (58%) have survived at median follow-up of 29 (15-50) months. Lymphadenopathic Kaposi sarcoma, the most common clinical presentation in children in eastern Africa, was associated with the best outcomes. Kaposi sarcoma with woody edema had a more chronic disease course, whereas visceral disease and Kaposi sarcoma with more than 20 widespread 'disseminated' skin/ oral lesions were independently associated with increased mortality. Identifying risk factors associated with unfavorable outcomes may be critical to determining which patients will require alternative therapeutic strategies [41] .
Timely ART initiation in individuals with HIVrelated malignancies reduces morbidity associated with opportunistic infections and improves overall survival. However, preexisting HIV-associated organ dysfunction, coexistence of opportunistic infections, compound immunosuppression caused by HIV and chemotherapy, as well as drug interactions between ART and chemotherapy and overlapping treatmentrelated toxicities make management of patients with HIV and cancer complex. A recent study suggests coadministration of chemotherapy with ART based on integrase strand-transfer inhibitors or nonnucleoside reverse transcriptase inhibitors but not boosted protease inhibitors results in better safety profiles and higher suppressed viral replication [39] .
Adult survivors of childhood/adolescent cancer have a lifelong increased morbidity and mortality as well as amplified risk of secondary malignancy [42] . Morbidity may be multisystem impacting on cardiorespiratory, skeletal, renal, neurocognitive, endocrine, and reproductive health compounded with significant psychosocial issues affecting mental health [43 & ]. Annual reviews are recommended for survivors of childhood cancer for screening, prevention, and treatment of late effects; however, uptake following transition to adult care is poor [44] . AYALHIV who survived malignancy face similar issues compounded by risk of cumulative long-term sequelea of HIV. Potentially, they have an increased risk of a secondary malignancy due to their underlying immune dysregulation and require enhanced support during transition to ensure retention in care and viral suppression.
PRIMARY AND SECONDARY PREVENTION
Early HIV diagnosis and timely ART may substantially reduce the risk of AIDS-defining cancers [5,6 & ,10,11,45 & ]. Unlike for HPV, HBV, and HCV, there are no vaccines or specific treatment for EBV and HHV-8, and early access to suppressive ART remains the most important preventive measure for cancers related to these infections.
High-risk variants of human papilloma virus
The high global prevalence of persistent hrHPV infection in both female and male AYALHIV [33,34 & ,46,47,35] and high proportion of high-grade precancerous lesions [35] highlight the importance of sex-neutral HPV vaccination. HPV vaccination induces good HPV-specific cell-mediated immune responses in AYALHIV, compared to HIV-uninfected age-matched controls; although, three rather than two doses are still recommended for AYALHIV due to a data gap [48] . Currently, only 11 (6%) countries vaccinate males in their national immunization programs [ && ]. A study from Saudi Arabia showed that male circumcision may play role in reduction of HPV infection, penile cancers, and cervical cancer among women with circumcised partners [53] . Screening for anal cancers is not routinely recommended; although, some experts suggest that this might be effective [54 & ,55] . There is an urgent need of prospective studies validating different approaches for prevention and screening of cervical and anogenital cancers.
Hepatitis B and C
Occurrence of HCC early in adulthood underlines the importance of primary prevention with HBV vaccination and screening for chronic HBV and HCV coinfection. Systematic screening for HBV and HCV infection is limited in most sub-Saharan African countries [56 & ]. Hepatitis B vaccination from birth with serological monitoring and boosting when appropriate, and education around prevention of HCV acquisition should be embedded within the life span care of those living with HIV. There is no consensus on HCC screening; although, 6 monthly liver ultrasounds and alpha-fetoprotein are supported by WHO guidance [38, 57] . Reducing risk of HCC includes HBV viral suppression with tenofovir-based regimens, avoidance of excessive alcohol and weight optimization. Increased advocacy for rapid access to curative direct-acting antivirals for HCV for coinfected adolescents is urgently required.
Knowledge, awareness, and uptake of sexual and reproductive health services (SRS) is insufficient among young people [58, 59] . Enhanced counselling, integration, or linkage to SRS can improve the uptake of voluntary male circumcision and cervical cancer screening [60] . AYALHIV require access to 'youth friendly' SRS integrated within multidisciplinary HIV care that includes primary prevention packages addressing vaccination, ART adherence, smoking [33] , alcohol and substance use [61] , weight management, and where appropriate screening for HPV, HBV, and HCV-related malignancies.
CONCLUSION
People living with HIV, including adolescents and young adults, are at increased risk of malignancy, due to immune dysregulation and the persistence of oncogenic viruses. While the excess cancer risk is reduced with suppressive ART, ART coverage is still suboptimal in many settings, and AYALHIV have the lowest rates of engagement with each aspect of the HIV care cascade. Improving HIV diagnosis, linkage, and retention in care on sustained suppressive ART for AYALHIV remains the most important cancer preventive measure. However, this must go hand in hand with integrated cancer screening and education programs including prevention of traditional cancer modifiable risk factors for a vulnerable population who currently face an increased life time risk of malignancy, while they negotiate their transition to adulthood living with HIV. Increased awareness among healthcare workers and prompt investigation of suggestive symptoms is needed to diagnose cancers at early stages. In the era of effective ART, AYALHIV should have access to cancer treatment and supportive care compared to their uninfected peers. 
